Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel F Carr

Showing results (21-30 of 45) with videos related to

Pageof 5
Sort By:
Current Opinion in Allergy and Clinical Immunology|May 16, 2024
Greater mechanistic understanding of the cutaneous pathogenesis of Stevens-Johnson syndrome/toxic epidermal necrolysis can shed light on novel therapeutic strategies: a comprehensive reviewEmeka D Ogiji, Nourah Aboheimed, Kehinde Ross, et al.
Molecular Biology Reports|January 25, 2024
The association of ABCB1 gene polymorphism with clinical response to carbamazepine monotherapy in patients with epilepsyHaroon Ur Rashid, Shakir Ullah, Daniel F Carr, et al.
The Journal of Antimicrobial Chemotherapy|February 4, 2020
Genetic influence of ABCG2, UGT1A1 and NR1I2 on dolutegravir plasma pharmacokineticsEmilie R Elliot, Megan Neary, Laura Else, et al.
British Journal of Clinical Pharmacology|November 20, 2020
Evaluation of clinical and genetic factors in the population pharmacokinetics of carbamazepineVincent L M Yip, Henry Pertinez, Xiaoli Meng, et al.
Rheumatology (Oxford, England)|October 21, 2024
Infliximab vs interferon-α in the treatment of Behçet's syndrome: clinical data from the BIO-BEHÇET'S randomized controlled trialRobert J Moots, Farida Fortune, Richard Jackson, et al.
Antimicrobial Agents and Chemotherapy|November 13, 2013
Population pharmacokinetic and pharmacogenetic analysis of nevirapine in hypersensitive and tolerant HIV-infected patients from MalawiLaura Dickinson, Masautso Chaponda, Daniel F Carr, et al.
Rheumatology and Immunology Research|July 3, 2025
Predicting response to infliximab and interferon-α in Behçet's syndrome: An exploratory analysis from the BIO-BEHÇET'S randomized controlled trialRobert J Moots, Farida Fortune, Richard Jackson, et al.
Clinical and Experimental Dermatology|March 8, 2025
Co-Production of the 'My SJS Passport' to Support Survivors of Stevens-Johnson Syndrome (SJS) Post Diagnosis and Beyond - A Proof of Concept StudyAnita Hanson, Lucy Hampson, Jane Evely, et al.
The Journal of Dermatology|June 3, 2023
TNF-α induced extracellular release of keratinocyte high-mobility group box 1 in Stevens-Johnson syndrome/toxic epidermal necrolysis: Biomarker and putative mechanism of pathogenesisGospel Nwikue, Anna Olsson-Brown, Nourah Aboheimed, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|January 31, 2013
Association of human leukocyte antigen alleles and nevirapine hypersensitivity in a Malawian HIV-infected populationDaniel F Carr, Mas Chaponda, Andrea L Jorgensen, et al.
Pageof 5

Showing results (21-30 of 45) with videos related to

Sort By:
Pageof 5
Current Opinion in Allergy and Clinical Immunology|May 16, 2024
Greater mechanistic understanding of the cutaneous pathogenesis of Stevens-Johnson syndrome/toxic epidermal necrolysis can shed light on novel therapeutic strategies: a comprehensive reviewEmeka D Ogiji, Nourah Aboheimed, Kehinde Ross, et al.
Molecular Biology Reports|January 25, 2024
The association of ABCB1 gene polymorphism with clinical response to carbamazepine monotherapy in patients with epilepsyHaroon Ur Rashid, Shakir Ullah, Daniel F Carr, et al.
The Journal of Antimicrobial Chemotherapy|February 4, 2020
Genetic influence of ABCG2, UGT1A1 and NR1I2 on dolutegravir plasma pharmacokineticsEmilie R Elliot, Megan Neary, Laura Else, et al.
British Journal of Clinical Pharmacology|November 20, 2020
Evaluation of clinical and genetic factors in the population pharmacokinetics of carbamazepineVincent L M Yip, Henry Pertinez, Xiaoli Meng, et al.
Rheumatology (Oxford, England)|October 21, 2024
Infliximab vs interferon-α in the treatment of Behçet's syndrome: clinical data from the BIO-BEHÇET'S randomized controlled trialRobert J Moots, Farida Fortune, Richard Jackson, et al.
Antimicrobial Agents and Chemotherapy|November 13, 2013
Population pharmacokinetic and pharmacogenetic analysis of nevirapine in hypersensitive and tolerant HIV-infected patients from MalawiLaura Dickinson, Masautso Chaponda, Daniel F Carr, et al.
Rheumatology and Immunology Research|July 3, 2025
Predicting response to infliximab and interferon-α in Behçet's syndrome: An exploratory analysis from the BIO-BEHÇET'S randomized controlled trialRobert J Moots, Farida Fortune, Richard Jackson, et al.
Clinical and Experimental Dermatology|March 8, 2025
Co-Production of the 'My SJS Passport' to Support Survivors of Stevens-Johnson Syndrome (SJS) Post Diagnosis and Beyond - A Proof of Concept StudyAnita Hanson, Lucy Hampson, Jane Evely, et al.
The Journal of Dermatology|June 3, 2023
TNF-α induced extracellular release of keratinocyte high-mobility group box 1 in Stevens-Johnson syndrome/toxic epidermal necrolysis: Biomarker and putative mechanism of pathogenesisGospel Nwikue, Anna Olsson-Brown, Nourah Aboheimed, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|January 31, 2013
Association of human leukocyte antigen alleles and nevirapine hypersensitivity in a Malawian HIV-infected populationDaniel F Carr, Mas Chaponda, Andrea L Jorgensen, et al.
Pageof 5